Pictet Asset Management (Switzerland)’s Rigel Pharmaceuticals RIGL Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,900	Closed	-$22K	–	2010
2022 Q3	$22K	Hold	1,900	–	–	﹤0.01%	1559
2022 Q2	$21K	Hold	1,900	–	–	﹤0.01%	1566
2022 Q1	$57K	Hold	1,900	–	–	﹤0.01%	1649
2021 Q4	$50K	Hold	1,900	–	–	﹤0.01%	1696
2021 Q3	$69K	Buy	+1,900	New	+$74.8K	﹤0.01%	1713

Other funds holding RIGL

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s RIGL Position: Q4 2022 in Review

Pictet Asset Management (Switzerland) sold out of Rigel Pharmaceuticals (RIGL) in Q4 2022, closing a stake of 1,900 shares — an estimated $22K sold.

Pictet Asset Management (Switzerland) first reported a position in RIGL in Q3 2021 and held it in 5 quarters. The position peaked at $69K in Q3 2021. 118 funds tracked by Wall St. Rank hold RIGL as of Q4 2022.

Pictet Asset Management (Switzerland) reported no remaining Rigel Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Pictet Asset Management (Switzerland) sold 1,900 Rigel Pharmaceuticals shares in Q4 2022, an estimated $22K.
Pictet Asset Management (Switzerland) first reported a position in Rigel Pharmaceuticals in Q3 2021 and held it in 5 quarters.
Pictet Asset Management (Switzerland)'s Rigel Pharmaceuticals position peaked at $69K in Q3 2021.
118 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2022.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q4 2022, filed 13 Feb 2023.